Risk Intelligence
Core Model
D+
53 / 100
Restricted
How strong and defensively sound is the company?
Weaker than most covered companies on this measure.
Suggestions
REGN · NASDAQ
REGENERON PHARMACEUTICALS INC
Private betaSector unavailable · Industry unavailable
$781.49
-1.48%
Close on Sep 11, 2026
Watch
Updated 6/30/2026
Long-term research evidence only. No price targets, no trading signals, no recommendations.
Investment Report Card
REGENERON PHARMACEUTICALS INC
Sector unavailable · Data confidence good
34 / 100
Rank #560 of 1,152 qualified companies
Top 81% · Not Currently Suggested
Long-Term Potential
Research Model
C
61 / 100
Not Scored
Does the business have the characteristics needed to create value over many years?
Around the middle of the covered universe.
Fundamental Momentum
Research Model
F
37 / 100
Not Scored
Is the underlying business getting stronger or weaker?
Weaker than most covered companies on this measure.
Ownership Intelligence
Supplemental Intelligence
C+
67 / 100
Positive disclosed activity
What are important owners actually doing?
Around the middle of the covered universe.
Valuation Intelligence
Research Model
D+
54 / 100
Reasonable
Is today's price reasonable?
Weaker than most covered companies on this measure — and valuation is researched separately from the Suggested Investment Score.
Capital Returns Intelligence
Research Model
C−
57 / 100
Favorable Capital Returns
How effectively does the company reward shareholders?
Around the middle of the covered universe — and capital returns are researched separately from the Suggested Investment Score.
Why it stands out
- More disclosed holders are new or increasing than reducing or exiting.
What holds it back
No weakening evidence is recorded in today's readings.
Long-term view
REGENERON PHARMACEUTICALS INC scores 61 on Long-Term Potential (C), described by the research model as not scored. This describes business characteristics only — it is not a forecast of future returns.
Ownership view
Disclosed ownership evidence reads 67 (C+): Positive disclosed activity. 4 tracked managers disclosed a position in the latest reporting period. Ownership filings are historical disclosures, not signals.
Valuation view
REGENERON PHARMACEUTICALS INC reads 54 out of 100 on Valuation Intelligence, recorded as Reasonable. The stock currently trades below most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
Capital returns view
REGENERON PHARMACEUTICALS INC reads 57 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend and a share count falling about 0.9% a year. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
What changed
No meaningful recorded changes in the stored history.
Risk Intelligence is a core model, Long-Term Potential, Fundamental Momentum, Valuation Intelligence and Capital Returns Intelligence are research models, and Ownership Intelligence is supplemental descriptive evidence. Valuation Intelligence and Capital Returns Intelligence each contribute 0% to the Suggested Investment Score. Nothing here is a recommendation.
Compare REGN with other companiesResearch Collections
This company does not currently satisfy any collection rule. That is a stored research result, not a judgement about the business.
Browse collectionsAbout a minute to read
The 60-Second Investment Brief
Written from stored research readings only. No hype. No trading signals. Just better evidence.
Why it's interesting
REGENERON PHARMACEUTICALS INC (REGN) scores 34 out of 100 and ranks #560 of 1,152 qualified companies today. That places it in the top 81% of ranked companies. The stored tier for that score is not currently suggested.
Business strength
Risk Intelligence reads 53 out of 100 (D+), recorded as restricted. Weaker than most covered companies on this measure.
Long-term opportunity
Long-Term Potential reads 61 out of 100 (C), recorded as not scored. Around the middle of the covered universe.
What's improving or weakening
Fundamental Momentum reads 37 out of 100 (F), recorded as not scored. Weaker than most covered companies on this measure.
What important owners are doing
Ownership Intelligence reads 67 out of 100 (C+), recorded as positive disclosed activity. Around the middle of the covered universe.
What kind of price you'd be paying
Valuation currently appears reasonable: Valuation Intelligence reads 54 out of 100 (D+), recorded as Reasonable. REGENERON PHARMACEUTICALS INC reads 54 out of 100 on Valuation Intelligence, recorded as Reasonable. The stock currently trades below most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value. Valuation Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
How the company rewards shareholders
Capital Returns Intelligence reads 57 out of 100 (C−), recorded as Favorable Capital Returns. REGENERON PHARMACEUTICALS INC reads 57 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend and a share count falling about 0.9% a year. Capital Returns Intelligence is a research model and contributes nothing to the Suggested Investment Score or the daily ranking.
What could go wrong
No weakening factors are recorded in today's stored readings, and data confidence is good. Absence of a recorded weakness is not evidence of safety.
Bottom line
No individual layer reaches the strongest band today. Risk Intelligence and Fundamental Momentum remain the main area to watch. Separately from the score, valuation reads reasonable at today's price.
Composite discovery model
Pro Investor Score
Pro Investor Score™
34 / 100
Not Currently Suggested
A 0–100 composite discovery score combining Risk Intelligence, Long-Term Potential, Fundamental Momentum, and Ownership Intelligence. It helps rank qualified companies for further research and does not predict future returns.
- Rank
- #560 of 694
- Percentile
- Top 81%
- Ranking updated
- September 12, 2026
329Rank weakened by 329 positions. Rank weakened by 329 positions.
- Risk Intelligence
- 53
- Long-Term Potential
- 61
- Fundamental Momentum
- 37
- Ownership Intelligence
- 67
30% contribution
30% contribution
20% contribution
20% contribution
Ownership Intelligence
67 / 100 · Positive · 20% of the Pro Investor Score
SUPPLEMENTAL / DESCRIPTIVE INTELLIGENCE
Coverage: Good
- Elite Investor Activity
- 63 · Moderately Positive
- Institutional Activity
- 79 · Positive
- Insider Activity
- Insufficient Data
- Strategic Ownership
- Insufficient Data
50% of Ownership Intelligence · 10% of the total score
Tracked professional-manager activity is moderately positive.
20% of Ownership Intelligence · 4% of the total score
Broad institutional evidence from resolved filings is positive.
15% of Ownership Intelligence · 3% of the total score
No discretionary insider transactions are stored for this company, so this evidence is unavailable rather than neutral.
15% of Ownership Intelligence · 3% of the total score
No qualifying major-holder filings are stored, so this evidence is unavailable rather than neutral.
Ownership Intelligence summarizes publicly disclosed activity among professional investment managers, broader institutions, company insiders, and significant strategic owners. It adds context to investment research but is not a validated predictor of future performance. Ownership information is publicly reported with a delay; the latest applicable reporting period is 2026-06-30, publicly disclosed 9/11/2026. Congressional activity is unavailable pending legal review and contributes nothing to this reading.
Why it ranks here
No component ranks in the top quartile of the qualified universe.
What holds it back
Risk Intelligence is less favourable
Defensive characteristics rank below the middle of the qualified universe.
Fundamental Momentum is softer
Reported business trends rank below the qualified median.
Ownership evidence is not uniformly supportive
The combined disclosed ownership evidence ranks below the qualified median.
COMPOSITE DISCOVERY MODEL — RESEARCH STAGE · Data coverage Excellent. Rankings are recalculated daily using the latest available information. Individual components may update at different frequencies based on when new financial and ownership data becomes available.
Researched separately
Valuation Intelligence 54 · Reasonable
RESEARCH MODEL
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
Researched separately
Capital Returns Intelligence 57 · Favorable Capital Returns
RESEARCH MODEL
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
Score explanation
Why this company scores the way it does
Four research areas carry fixed weights. Each area is compared against every other eligible company, then weighted. The four contributions below add to 34.3 of the stored score (34.3).
Risk Intelligence
30% of the score · contributes 2.5 points
How strong and defensively sound is the company?
Stands at the 8 percentile of eligible companies · stored reading 53 · 7% of this company’s total score
How financially sturdy the company has been when conditions turned against it.
How this area is measured
Risk Intelligence reads stored balance-sheet strength, historical downside behaviour and the company's price-risk grouping. A stronger reading describes past resilience; it does not protect against future losses.
Full methodologyLong-Term Potential
30% of the score · contributes 20.6 points
Does the business have the characteristics needed to create value over many years?
Stands at the 69 percentile of eligible companies · stored reading 61 · 60% of this company’s total score
Whether the business has the durable characteristics long-term owners look for.
How this area is measured
Long-Term Potential reads durability characteristics such as profitability consistency, cash generation and reinvestment capability over multiple reported periods.
Full methodologyFundamental Momentum
20% of the score · contributes 4.7 points
Is the underlying business getting stronger or weaker?
Stands at the 23 percentile of eligible companies · stored reading 37 · 14% of this company’s total score
Whether the reported business results have been getting stronger or weaker.
How this area is measured
Fundamental Momentum compares recent reported fundamentals with the company's own earlier periods, so improvement or deterioration is measured against its history rather than against a forecast.
Full methodologyOwnership Intelligence
20% of the score · contributes 6.6 points
What are important owners actually doing?
Stands at the 33 percentile of eligible companies · stored reading 67 · 19% of this company’s total score
What large reporting owners have actually been doing with their positions.
How this area is measured
Ownership Intelligence reads public ownership filings: how many tracked reporting owners hold the company, and whether they were adding, holding, reducing or exiting in the latest disclosed period.
Full methodology
What is helping the score
- Long-Term Potential — 69 percentile, adding 20.6 points.
What deserves attention
- Risk Intelligence — 8 percentile, adding only 2.5 of a possible 30 points.
- Fundamental Momentum — 23 percentile, adding only 4.7 of a possible 20 points.
- Ownership Intelligence — 33 percentile, adding only 6.6 of a possible 20 points.
Outside the score
Additional research — not currently included in the primary Suggested Investment Score.
- Valuation Intelligence — REGENERON PHARMACEUTICALS INC reads 54 out of 100 on Valuation Intelligence, recorded as Reasonable. The stock currently trades below most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.
- Capital Returns Intelligence — REGENERON PHARMACEUTICALS INC reads 57 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend and a share count falling about 0.9% a year.
Pro Investor Intelligence™
Reported by insiders, large shareholders and professional funds. Shown beside our research, never blended into it.
Loading professional-investor activity…
Stored snapshots only
What changed
Research-score history available since September 2026.
Stored research history does not yet cover a full 30 days comparison for this company.
A change is reported as meaningful at 8 score points, 5 rank places, or any change of research classification. Nothing here is a recommendation to buy or sell.
Learn the metrics on this page
Plain-English definitions, with the formula and the limitations of each measure.
Fifth research lens · outside the score
Valuation Intelligence
Valuation Intelligence
Is today's price reasonable?
Valuation Intelligence is currently researched separately and does not affect the Suggested Investment Score or daily ranking.
54/ 100
Reasonable
RESEARCH MODEL
Excellent coverage
Compared with its history
60
Reasonable
Is this company expensive or inexpensive compared with its own history?
Compared with peers
53
Reasonable
How expensive is this stock compared with similar companies?
Earnings & cash flow
60
Reasonable
How much financial output does an investor receive relative to the price paid?
Growth-adjusted
40
Elevated
Does the company's growth help justify the valuation investors are paying?
REGENERON PHARMACEUTICALS INC reads 54 out of 100 on Valuation Intelligence, recorded as Reasonable. The stock currently trades below most of its own recent valuation history and above comparable companies. This describes the price being paid relative to the company's financials — it is not a forecast and not a fair value.
Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026
Valuation history
Stored readings only. The dashed line is this company's own median for the selected measure.
Only one stored valuation reading exists so far, so there is nothing to chart yet. Valuation history builds forward from activation rather than being reconstructed.
Current P/E 18.6x · own median 19.7x · peer median 16.2x
Valuation is inherently uncertain. A stock that appears inexpensive can continue falling, and a stock that appears expensive can continue rising. Valuation Intelligence provides context about the price investors are paying — it does not predict short-term market movements, and it never produces a fair value, a price target or a buy or sell range. Model VALUATION_INTELLIGENCE_V1.
Sixth research lens · outside the score
Capital Returns Intelligence
Capital Returns Intelligence
How effectively does the company reward shareholders?
Capital Returns Intelligence is researched separately and contributes 0% to the Suggested Investment Score, the daily rank or any ranking event.
57/ 100
Favorable Capital Returns
RESEARCH MODEL
Excellent coverage
Dividend Quality
56
Moderate Capital Returns
Dividend reliability
Not enough years of dividend history to measure growth.
Buyback Effectiveness
73
Strong Capital Returns
Do buybacks actually reduce shares?
Dilution Control
54
Moderate Capital Returns
Is your ownership share protected?
Capital Return Sustainability
48
Moderate Capital Returns
Can the cash flow support it?
Shareholder Yield
45
Moderate Capital Returns
Cash returned versus company value
REGENERON PHARMACEUTICALS INC reads 57 out of 100 on Capital Returns Intelligence (Favorable Capital Returns), reflecting a dividend and a share count falling about 0.9% a year.
How returned cash was used
Dividends $378.50M · net repurchases $3.15B · total returned $3.52B · 94% of free cash flow
Price data through September 11, 2026 · Financial data through the quarter ended June 30, 2026
Capital returns history
Stored readings only. History builds forward from activation rather than being reconstructed.
Only one stored reading exists for this measure so far, so there is nothing to chart yet.
Why higher yield isn't always better
A very high dividend yield may reflect a falling share price or an unsustainable payout. Capital Returns Intelligence emphasizes consistency and sustainability rather than simply rewarding the highest yield.
Why buybacks can be misleading
Announced or gross buyback spending does not always mean shareholders are gaining ownership. Companies can simultaneously issue shares through employee compensation or acquisitions. Suggested Investments therefore considers actual share-count changes alongside repurchase spending.
What these terms mean
- Dividend Yield
- The annual dividend relative to the current share price.
- Payout Ratio
- The share of company earnings used to pay dividends.
- Free Cash Flow Payout
- How much of the company's available cash is being used for dividends.
- Share Repurchases
- When a company buys back its own stock.
- Dilution
- When the number of shares increases, reducing each existing share's percentage ownership of the company.
- Shareholder Yield
- A combined view of dividends and net share repurchases relative to the company's market value.
Capital Returns Intelligence describes how a company returns capital to shareholders. It is not a measure of stock-price performance, it does not predict future returns, and a strong reading is never a recommendation to buy. Dividends and repurchases can be reduced or stopped at any time. Model CAPITAL_RETURNS_INTELLIGENCE_V1, contributing 0% to the Pro Investor Score.
Stored daily snapshots only
Ranking history
| Today | #560 | Score 34 |
|---|---|---|
| 30 days ago | Not ranked | No stored score |
| 90 days ago | Not ranked | No stored score |
| First suggested | Not yet suggested | |
| Highest rank | #560 | |
In the company’s own words
What this company does
This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, "Regeneron," "Company," "we," "us," and "our"), and actual events or results may differ materially from these forward-looking statements. Words such as "anticipate," "expect," "intend," "plan," "believe," "seek," "estimate," variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. These statements concern, and these risks and uncertainties include, among others:
competing products and product candidates (including biosimilar products) that may be superior to, or more cost effective than, products marketed or otherwise commercialized by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Products") and product candidates being developed by Regeneron and/or its collaborators or licensees (collectively, "Regeneron's Product Candidates");
uncertainty of the utilization, market acceptance, and commercial success of Regeneron's Products and Regeneron's Product Candidates and the impact of studies (whether conducted by Regeneron or others and whether mandated or voluntary) or recommendations and guidelines from governmental authorities and other third parties or other factors beyond Regeneron's control on the commercial success of Regeneron's Products and Regeneron's Product Candidates;
the nature, timing, and possible success and therapeutic applications of Regeneron's Products and Regeneron's Product Candidates and research and clinical programs now underway or planned, including without limitation those discussed or referenced in this report, Regeneron's and its collaborators' earlier-stage programs, and the use of human genetics in Regeneron's research programs;
Quoted from the business section of this company’s 10-K filed February 4, 2026. Read the filing
Four distinct intelligence areas
The IA view
Risk Intelligence
Production core
53
Fundamentally Qualified
+14.3 vs Jun 30, 2026
Business Quality qualification score from the locked IA Defensive Research Core. Price Risk stays a separate category and is never blended in.
As of Sep 11, 2026
Long-Term Potential
Research model
61
Elite Compounder
No prior period to compare
Durable business economics and reinvestment characteristics. Independent external validation is pending.
As of Sep 11, 2026
Fundamental Momentum
Research model
37
Deteriorating
No prior period to compare
Direction and breadth of change in underlying business fundamentals. Not a price-momentum signal.
As of Sep 11, 2026
Elite Investor Activity
Supplemental
63
Mid range
0 vs Jun 30, 2026
Only 4 tracked managers disclosed a position — treat as limited coverage.
As of Sep 11, 2026
Company intelligence
REGN score history
Each area is measured and reported separately. No combined score exists.
REGN intelligence history from 2023-09-30 to 2026-09-11. Risk Intelligence 53.2 on 2026-09-11, up 14.3 from 38.9 on 2026-06-30. Long-Term Potential 60.9 on 2026-09-11. Fundamental Momentum 36.8 on 2026-09-11. Elite Investor Activity 62.5 on 2026-09-11, unchanged 0 from 62.5 on 2026-06-30. Each area is reported separately and is never combined into a single score.
Risk Intelligence 53.2 as of Sep 11, 2026 (+14.3 vs prior period) · Production core
Long-Term Potential 60.9 as of Sep 11, 2026 · Research model
Fundamental Momentum 36.8 as of Sep 11, 2026 · Research model
Elite Investor Activity 62.5 as of Sep 11, 2026 (0 vs prior period) · Supplemental
Share price
REGN price history
Closing prices adjusted for splits and dividends. Past prices do not indicate future results.
- 6M change
- +4.9%
- 1Y change
- +38.2%
- 3Y change
- -4.5%
- 5Y change
- +20.8%
- Max change
- +111.3%
Last stored close $781.49 · +38.2% over the selected range · 52 sessions shown
Balanced evidence
Why IA likes it
- More disclosed holders are new or increasing than reducing or exiting.
Risk and uncertainty
What IA doesn’t like
- No specific negative evidence is available. This is not evidence of low risk.
What would change our view
- Business Quality falling below the frozen qualification threshold.
- Price Risk moving to a less favorable category.
- A sustained reversal in the Fundamental Momentum research evidence.
- New material public ownership disclosures.
Public filings · descriptive only
Elite Investor Activity
Reporting holders
1
New holders
1
Increasing
0
Reducing
0
Exiting
0
Coverage
Excellent
Positive disclosed activity · Report period 2016-12-31 · Public 12/22/2023
| Manager | Change | Portfolio weight | Rank | Disclosed |
|---|
Insufficient high-confidence manager coverage.
Objective stored changes
What changed
- Risk Intelligence
IA Defensive weakened
Business Quality qualification score moved from 38.9 to 37.2.
- Elite Investor Activity
Elite Investor Consensus strengthened
Disclosed agreement among tracked managers moved from 50 to 63 for the reporting period ending 2026-06-30.
- Elite Investor Activity
Elite Investor Consensus weakened
Disclosed agreement among tracked managers moved from 83 to 50 for the reporting period ending 2026-03-31.
- Elite Investor Activity
Elite Investor Consensus weakened
Disclosed agreement among tracked managers moved from 33 to 0 for the reporting period ending 2025-06-30.
- Elite Investor Activity
Tracked managers exited positions
2 tracked managers no longer disclosed a position for the reporting period ending 2025-06-30.
- Elite Investor Activity
Elite Investor Consensus weakened
Disclosed agreement among tracked managers moved from 58 to 33 for the reporting period ending 2025-03-31.
- Elite Investor Activity
Tracked managers exited positions
3 tracked managers no longer disclosed a position for the reporting period ending 2025-03-31.
- Elite Investor Activity
Elite Investor Consensus weakened
Disclosed agreement among tracked managers moved from 92 to 58 for the reporting period ending 2024-12-31.
- Elite Investor Activity
Tracked managers initiated positions
5 tracked managers first disclosed a position for the reporting period ending 2024-09-30.
Ownership timeline
No high-confidence public ownership events are available.
General research only. Not personalized advice. Public filings may be delayed, amended, incomplete, or reflect positions that have changed since the reporting date.